GenVivo
GenVivo is a private clinical-stage biopharmaceutical company developing off-the-shelf, non-integrating retroviral gene therapy immunotherapies for advanced solid tumors and B-cell malignancies, with lead candidate GEN2 in Phase 1/1b clinical trials.
- Company typePrivate
- Founded2023
- HeadquartersSan Marino, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
What GenVivo does
GenVivo is a private, clinical-stage biopharmaceutical company developing off-the-shelf gene therapy immunotherapies for cancer treatment. The company is built around its proprietary G-Volve platform, a non-integrating retroviral vector system that delivers dual therapeutic payloads (a prodrug-activated suicide gene HSV-eTK combined with immunostimulatory cytokines) via intravenous administration, designed to generate immune effectors in vivo without requiring ex vivo cell processing or genomic integration.
The company's pipeline includes four candidates: lead asset GEN2 (encoding HSV-eTK and GM-CSF), currently in a US Phase 1/1b trial (NCT06391918) for advanced solid tumors following 48-patient Phase 1 testing in Asia; GEN-1013 (HSV-eTK + IL-12), in preclinical development with IND filing planned for mid-2026; GEN-1018 (immuno-gene therapy); and GEN-310 (in vivo CAR-T/NK vector for B-cell malignancies), currently in IND-enabling stage. GenVivo targets oncology patients with advanced or refractory solid tumors and hematologic malignancies, with clinical investigation conducted at cancer centers including City of Hope National Medical Center.
The business model is pre-revenue and pre-commercial, with GenVivo generating no product sales. Anticipated future revenue will derive from commercialization of its gene immunotherapy pipeline candidates subject to regulatory approval. The company historically operated a vertically-integrated model with in-house cGMP manufacturing, clinical operations, and R&D; however, the Southern California manufacturing facility was closed in February 2026, with assets auctioned via Tiger Group. GenVivo is headquartered in San Marino, California, employs 11-50 people, and is privately-held with founder/owner-operated ownership and no disclosed institutional investor backing in available sources.
GenVivo firmographics
Firmographics- Name
- GenVivo
- Legal name
- GenVivo, Inc.
- Website
- https://genvivoinc.com
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- GenVivo is a private clinical-stage biopharmaceutical company developing off-the-shelf, non-integrating retroviral gene therapy immunotherapies for advanced solid tumors and B-cell malignancies, with lead candidate GEN2 in Phase 1/1b clinical trials.
- Ownership category
- akta.pro rank
GenVivo industry classification
Industry- Product category
- Cancer Gene Immunotherapy
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches) (HLAAACAF)
- akta.pro secondary industries
- Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream) (HLAAACAN), Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods) (HLAAABAL), NK Cell Therapies (HLAAABAD)
Keywords
Where GenVivo is headquartered
LocationHeadquarters
- HQ city
- San Marino
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
GenVivo business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Gene Therapy Product Revenue (Future): GenVivo is a pre-revenue, clinical-stage private biopharmaceutical company. Its primary anticipated revenue stream will derive from the commercialization of its oncology gene immunotherapy pipeline candidates (GEN2, GEN-1013, GEN-310), once regulatory approval is obtained. The company maintains vertically integrated cGMP manufacturing capabilities in-house.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
GenVivo product offering
Product offeringCore offering
GenVivo is a clinical-stage biopharmaceutical company developing off-the-shelf, intravenously administered gene vector immunotherapies for cancer. Its lead candidate GEN2 combines HSV-eTK and GM-CSF in a non-replicating retroviral vector and is in Phase 1/2 clinical trials (NCT06391918) for advanced solid tumors. Pipeline candidates GEN-1013, GEN-310, and GEN-1018 extend the approach to IL-12 delivery and in vivo CAR-T/NK generation for B-cell malignancies, all built on the proprietary G-Volve non-integrating retroviral vector platform.
Product overview
GenVivo is a clinical-stage biopharmaceutical company developing an off-the-shelf vector platform for cancer gene medicine immunotherapies. The company's portfolio includes multiple product candidates: GEN2 (HSV-eTK/GM-CSF retroviral vector in Phase 1/2 clinical trial for solid tumors), GEN-1013 (IL-12 encoding vector in preclinical development with IND filing planned mid-2026), GEN-310 (in vivo CAR-T/NK vector for B cell malignancies in IND-enabling stage), and GEN-1018. These are built on the proprietary G-Volve non-integrating retroviral vector platform technology that enables systemic administration of therapeutic genes without genome integration. The company maintains fully integrated in-house capabilities including cGMP manufacturing, process development, and clinical operations.
Differentiator
Problem solved
Functional benefit
Products and services
- GEN2 Non-replicating mRNA retroviral gene therapy vector encoding HSV-eTK and GM-CSF, administered intravenously with valganciclovir prodrug to kill tumors and stimulate patient-specific immune responses; in Phase 1/2 trial for advanced solid tumors.
- GEN-1013
Quantifiable outcome
- GEN2 was well-tolerated with minimal toxicity and no dose-dependent Treatment Emergent Adverse Events (TEAEs) across a 1000-fold dose range in 48 patients; no toxicity-defined Maximum Tolerated Dose (MTD) was identified
- +3 more outcomes
Companies that use GenVivo
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles2 records
GenVivo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
GenVivo partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- City of Hope National Medical CentercoreCity of Hope National Medical Center in Duarte, CA serves as a key clinical trial site for GenVivo's GEN2 Phase 1/1b clinical trial (NCT06391918). Dr. Daneng Li, Associate Professor and Hepatobiliary Lead and Co-Director of the Neuroendocrine Tumor Program at City of Hope, is a co-investigator and provided commentary on the trial initiation. The partnership enables GenVivo to conduct clinical investigation of its GEN2 gene vector immunotherapy in patients with advanced solid tumors.
Scale indicators4 records
Recent moves6 records
Expansion highlights5 records
GenVivo competitors and assessment
Company assessmentMarket position
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights7 records
Customer concentration
GenVivo social profiles
Digital presenceGenVivo financial estimates
Financial estimateRevenue estimate
Valuation estimate
GenVivo leadership team
Management profileNumber of profiles
Profiles12 records
GenVivo funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
GenVivo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about GenVivo
What does GenVivo do?
GenVivo is a clinical-stage biopharmaceutical company developing off-the-shelf, intravenously administered gene vector immunotherapies for cancer. Its lead candidate GEN2 combines HSV-eTK and GM-CSF in a non-replicating retroviral vector and is in Phase 1/2 clinical trials (NCT06391918) for advanced solid tumors. Pipeline candidates GEN-1013, GEN-310, and GEN-1018 extend the approach to IL-12 delivery and in vivo CAR-T/NK generation for B-cell malignancies, all built on the proprietary G-Volve non-integrating retroviral vector platform.
Is GenVivo a public or private company?
GenVivo is a private company. It is classified as family owned and is currently operating.
When was GenVivo founded?
GenVivo was founded in 2023. It employs 11 to 50 people.
Where is GenVivo based?
GenVivo is headquartered in San Marino, United States, in the North America region.
How does GenVivo make money?
One revenue line is on record: gene Therapy Product Revenue (Future).
Does GenVivo have an API?
No public API is recorded for GenVivo.
What industry is GenVivo in?
GenVivo's product category is Cancer Gene Immunotherapy. Its primary akta.pro industry code is HLAAACAF, Oncology Gene Therapies (incl. oncolytic vectors & gene-modified approaches), with a secondary code of HLAAACAN, Gene Therapy CMC/Process Development Platforms (capsid engineering, producer cell lines, plasmids, upstream/downstream). Its NAICS code is 541714 and its SIC code is 2836.